Pharmaceutical nanotechnology has revolutionized drug delivery by enabling precise control over pharmacokinetics, biodistribution, and therapeutic outcomes. Conventional drug formulations face significant limitations including poor bioavailability, non-specific distribution, rapid clearance, and systemic toxicity. Nanotechnology-based drug delivery systems address these challenges through engineered nanocarriers that provide controlled release kinetics, targeted delivery to specific tissues or cells, and sustained therapeutic concentrations. This review examines emerging trends in pharmaceutical nanotechnology focusing on polymeric nanoparticles, lipid-based systems, and novel hybrid platforms designed for controlled, targeted, and sustained drug release applications. Key mechanisms governing drug release kinetics, including diffusion-controlled, swelling-controlled, and stimuli-responsive release, are critically analyzed. Targeting strategies encompassing passive accumulation via enhanced permeability and retention effects, active ligand-mediated targeting, and stimuli-responsive delivery are evaluated for their clinical relevance. Major therapeutic applications in oncology, infectious diseases, and chronic disorders demonstrate the translational potential of these platforms. Despite significant advances, challenges related to formulation complexity, scalability, reproducibility, regulatory approval, and long-term safety remain substantial barriers to clinical translation. Future research directions emphasize personalized nanomedicine, combination therapies, and advanced characterization techniques to bridge the gap between laboratory innovation and clinical implementation. This review provides a comprehensive analysis of current pharmaceutical nanotechnology trends essential for next-generation drug delivery systems.